Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

AGI-5198

Catalog No: tcsc1429

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1355326-35-0

Formula:
$C_{27}H_{31}FN_4O_2$

Pathway:
Metabolic Enzyme/Protease

Target:
Isocitrate Dehydrogenase (IDH)

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 34 mg/mL (73.50 mM)

Alternative Names:
IDH-C35

Observed Molecular Weight:
462.56

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

AGI-5198 is a novel **R132H-IDH1** inhibitor, used for cancer treatment.

In Vitro: Measurements of R-2HG concentrations in pellets of TS603 glioma cells demonstrates dose-dependent inhibition of the mutant IDH1 enzyme by AGI-5198. AGI-5198 does not impair colony formation of two patient-derived glioma lines that express only the wild-type IDH1 allele (TS676 and TS516)[1]. Cancer cells heterozygous for the IDH1(R132H) mutation exhibits less IDH-mediated production of NADPH, such that after exposure to ionizing radiation (IR), there are higher levels of reactive oxygen species, DNA double-strand breaks, and cell death compared with IDH1 wild-type cells. These effects are reversed by the IDH1(R132H) inhibitor AGI-5198[2].

In Vivo: AGI-5198 (450 mg/kg, p.o.) causes 50 to 60% growth inhibition of the tumor growth from human glioma xenografts. Tumors from AGI-5198- treated mice show reduced staining with an antibody against the Ki-67 protein. AGI-5198 does not affect the growth of IDH1 wild-type glioma xenografts[1].